MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
NASDAQ:MDXG - Nasdaq - US6024961012 - Common Stock - Currency: USD
Overall MDXG gets a fundamental rating of 5 out of 10. We evaluated MDXG against 555 industry peers in the Biotechnology industry. MDXG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. MDXG is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MDXG was profitable.
MDXG had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 14.86%, MDXG belongs to the top of the industry, outperforming 96.04% of the companies in the same industry.
Looking at the Return On Equity, with a value of 19.82%, MDXG belongs to the top of the industry, outperforming 96.22% of the companies in the same industry.
MDXG's Return On Invested Capital of 14.58% is amongst the best of the industry. MDXG outperforms 96.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.86% | ||
| ROE | 19.82% | ||
| ROIC | 14.58% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG's Profit Margin of 11.40% is amongst the best of the industry. MDXG outperforms 93.33% of its industry peers.
Looking at the Operating Margin, with a value of 12.86%, MDXG belongs to the top of the industry, outperforming 94.05% of the companies in the same industry.
MDXG's Operating Margin has been stable in the last couple of years.
The Gross Margin of MDXG (81.94%) is better than 85.95% of its industry peers.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.86% | ||
| PM (TTM) | 11.4% | ||
| GM | 81.94% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
MDXG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, MDXG has more shares outstanding
MDXG has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
MDXG has an Altman-Z score of 10.27. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
MDXG has a Altman-Z score of 10.27. This is amongst the best in the industry. MDXG outperforms 87.57% of its industry peers.
The Debt to FCF ratio of MDXG is 0.29, which is an excellent value as it means it would take MDXG, only 0.29 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.29, MDXG belongs to the top of the industry, outperforming 95.86% of the companies in the same industry.
MDXG has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.09, MDXG is not doing good in the industry: 64.14% of the companies in the same industry are doing better.
Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.29 | ||
| Altman-Z | 10.27 |
ROIC/WACC1.65
WACC8.81%
2.3 Liquidity
MDXG has a Current Ratio of 4.70. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MDXG (4.70) is comparable to the rest of the industry.
MDXG has a Quick Ratio of 4.13. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MDXG (4.13) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.7 | ||
| Quick Ratio | 4.13 |
3. Growth
3.1 Past
The earnings per share for MDXG have decreased strongly by -37.78% in the last year.
Looking at the last year, MDXG shows a small growth in Revenue. The Revenue has grown by 5.34% in the last year.
The Revenue has been growing slightly by 3.11% on average over the past years.
EPS 1Y (TTM)-37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)5.34%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%4.13%
3.2 Future
MDXG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.19% yearly.
MDXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.54% yearly.
EPS Next Y-12.95%
EPS Next 2Y7.74%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue Next Year8.51%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 22.21, which indicates a rather expensive current valuation of MDXG.
MDXG's Price/Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 94.77% of the companies in the same industry.
MDXG is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.21, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 18.48, which indicates a rather expensive current valuation of MDXG.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaply inside the industry as 93.15% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 21.70. MDXG is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.21 | ||
| Fwd PE | 18.48 |
4.2 Price Multiples
MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 95.32% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 95.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.23 | ||
| EV/EBITDA | 15.45 |
4.3 Compensation for Growth
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.74%
EPS Next 3Y8.19%
5. Dividend
5.1 Amount
No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.22
+0.11 (+1.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.18%
Inst Owner Change6.78%
Ins Owners1.74%
Ins Owner Change1.17%
Market Cap918.69M
Analysts81.82
Price Target12.24 (96.78%)
Short Float %3.44%
Short Ratio7.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.48%
Min EPS beat(2)-31.92%
Max EPS beat(2)6.95%
EPS beat(4)3
Avg EPS beat(4)9.74%
Min EPS beat(4)-31.92%
Max EPS beat(4)52.51%
EPS beat(8)7
Avg EPS beat(8)71.29%
EPS beat(12)9
Avg EPS beat(12)45.41%
EPS beat(16)12
Avg EPS beat(16)48.58%
Revenue beat(2)2
Avg Revenue beat(2)1.09%
Min Revenue beat(2)0.32%
Max Revenue beat(2)1.86%
Revenue beat(4)2
Avg Revenue beat(4)-0.5%
Min Revenue beat(4)-3.85%
Max Revenue beat(4)1.86%
Revenue beat(8)6
Avg Revenue beat(8)1.5%
Revenue beat(12)8
Avg Revenue beat(12)1.63%
Revenue beat(16)12
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)-10.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.6%
EPS NY rev (1m)0.61%
EPS NY rev (3m)-20.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.12%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)-0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.21 | ||
| Fwd PE | 18.48 | ||
| P/S | 2.61 | ||
| P/FCF | 14.23 | ||
| P/OCF | 14.02 | ||
| P/B | 4.53 | ||
| P/tB | 5.33 | ||
| EV/EBITDA | 15.45 |
EPS(TTM)0.28
EY4.5%
EPS(NY)0.34
Fwd EY5.41%
FCF(TTM)0.44
FCFY7.03%
OCF(TTM)0.44
OCFY7.13%
SpS2.39
BVpS1.37
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.86% | ||
| ROE | 19.82% | ||
| ROCE | 19.89% | ||
| ROIC | 14.58% | ||
| ROICexc | 27.36% | ||
| ROICexgc | 36.54% | ||
| OM | 12.86% | ||
| PM (TTM) | 11.4% | ||
| GM | 81.94% | ||
| FCFM | 18.33% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score5
Asset Turnover1.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.29 | ||
| Debt/EBITDA | 0.33 | ||
| Cap/Depr | 11.12% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 27.66 | ||
| Cash Conversion | 121.79% | ||
| Profit Quality | 160.71% | ||
| Current Ratio | 4.7 | ||
| Quick Ratio | 4.13 | ||
| Altman-Z | 10.27 |
F-Score5
WACC8.81%
ROIC/WACC1.65
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-12.95%
EPS Next 2Y7.74%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue 1Y (TTM)5.34%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%4.13%
Revenue Next Year8.51%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%
EBIT growth 1Y-18.47%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year25.32%
EBIT Next 3Y18.64%
EBIT Next 5YN/A
FCF growth 1Y533.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y659.04%
OCF growth 3YN/A
OCF growth 5YN/A